Giulia Centioni

Dr. Giulia Centioni


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SASümeyye Akçay
Sümeyye Akçay
AYArzu Dinç Yavaş
Arzu Dinç Yavaş
VCValerio Cipolloni
Valerio Cipolloni
Giulia CentioniGiulia Centioni
Giulia Centioni
RBRosa Grazia Bellomo
Rosa Grazia Bellomo
ACAlessandro Conforti
Alessandro Conforti
Osteoarthritis is a heterogeneous whole-joint disorder involving mechanical dysfunction, inflammatory signaling, extracellular matrix degradation, and abnormal subchondral bone remodeling. This narrative review evaluates peptide therapeutics by biological function and translational readiness. We synthesize evidence on immunomodulatory and pro-resolution peptides, growth-factor-derived and mimetic peptides, exploratory soft-tissue repair peptides, extracellular matrix-derived and biomimetic peptides, dietary peptide hydrolysates, and peptide-based delivery systems. Evidence from human osteoarthritis, experimental osteoarthritis, focal osteochondral defects, and broader inflammatory or tissue-repair settings is distinguished. Selected peptides show anti-inflammatory, anti-catabolic, or reparative effects in cell and animal models, but these findings do not establish clinical efficacy. Human studies predominantly examine oral collagen hydrolysates and report formulation-specific improvements in pain or function. Their interpretation is limited by small samples, analysis populations, short follow-up, and reporting quality. Investigational intra-articular peptides provide additional signals, although negative primary endpoints and exploratory structural analyses require caution. No peptide intervention reviewed has established reproducible structural disease modification in human osteoarthritis. Clinical translation requires independently replicated efficacy, adequate safety assessment, reproducible manufacturing, and prospective trials that distinguish symptomatic improvement from structural disease modification.

11 November 2026 in Rheumato
Verified
Journal Article
Open access
PDF file
MBMarco Bonifiacio
Marco Bonifiacio
VCValerio Cipolloni
Valerio Cipolloni
FMFilippo Messina
Filippo Messina
Giulia CentioniGiulia Centioni
Giulia Centioni
SHSyeda Maryam Hassny
Syeda Maryam Hassny
ACAlessandro Conforti
Alessandro Conforti
Guselkumab is a human monoclonal antibody directed against the p19 subunit of interleukin-23. This structured narrative review evaluates its pharmacologic rationale, efficacy, safety, durability, and therapeutic role in plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. PubMed/MEDLINE and Europe PMC were searched from inception through 18 September 2026 using broad and disease-specific strategies; ClinicalTrials.gov was searched to link trial families and identify ongoing studies. Records were screened for directness, design, distinct contribution, and clinical relevance. The final synthesis included 64 PubMed-indexed articles and the current US prescribing information. In plaque psoriasis, guselkumab produces high and durable skin clearance rates and has demonstrated superiority over active comparators at prespecified time points. In psoriatic arthritis, it improves peripheral arthritis, skin disease, enthesitis, dactylitis, function, and patient-reported outcomes; long-term trials show low observed radiographic progression, whereas evidence for axial disease remains less definitive. In Crohn’s disease and ulcerative colitis, phase 3 programs demonstrate clinical and endoscopic efficacy with intravenous or fully subcutaneous induction and subcutaneous maintenance. Long-term trial data support a stable safety profile, although infection screening, tuberculosis assessment, vaccination review, and indication-specific liver monitoring remain important. Guselkumab may be clinically relevant when skin, joint, and bowel inflammation coexist, but treatment should remain domain based because efficacy cannot be assumed to be equivalent across manifestations. Direct within-class comparisons, validated response biomarkers, and dedicated axial and disease-modification studies remain priorities.